Insider trade

Officer sold ~$1.59M of INCY shares in the open market

Traded Jan 5, 2026 · Filed Jan 7, 2026

IncyteINCY

~$1.59M
Reported value · 16K sh @ $101.70: 34K
Holds after · shares reported: +15.1%
stock since the trade · S&P 500 +11.1%, $101.79 → $117.14 on Oct 1

Why it stands out

Incyte's & Chief Medical Officer sold $1.59M of Incyte shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 5, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 7, 2026

Officer$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,589,978

Shares × reported transaction price

Timing vs results

69 days after results of Oct 28, 2025, 36 days before results of Feb 10, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $101.79 on Jan 5, 2026, 85% above its 52-week low and 6% below its high, little changed over the previous 30 trading days

52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 88% of the way up, from 250 adjusted closes. 30 trading days earlier: $101.32 on Nov 19, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Zynyz on Dec 17, 2025, 19 days before this trade.

New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-0.6%	+0.4%	-1.0%
30 days	+2.9%	+0.6%	+2.3%
90 days	-9.5%	-2.0%	-7.5%
180 days	+11.4%	+8.4%	+3.0%

Past results only. Not a forecast.

Source receipt

Record ID: 0001673776-26-000004
Filed / recorded: Jan 7, 2026, 9:03 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: INCYTE CORP
Issuer CIK: 879169
Ticker: INCY
Reporting person: Steven H Stein
Relationship: Officer
Officer title: EVP & Chief Medical Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jan 5, 2026
Transaction code: S
Shares / units: 15,634
Price per share: $101.70
Acquired / disposed: Disposed (D)
Shares owned after: 34,203
Ownership form: Direct
Amendment: No

Footnotes from the filing

This includes an aggregate of 34,203 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.